2 citations
,
March 2022 in “Journal of The European Academy of Dermatology and Venereology” This letter to the editor presents no new research results; it discusses a combination of dutasteride intralesional microinjections with oral minoxidil versus oral minoxidil alone for treating androgenetic alopecia in men.
January 2026 in “JPRAS Open” In this pilot study, PDLLA scalp microinjections showed improvement in physician-rated Global Aesthetic Improvement Scale scores over 12-24 weeks for 90% of patients with non-scarring alopecia, with no serious adverse events reported, although findings remain preliminary due to methodological limitations.
November 2025 in “Skin Appendage Disorders” In this study, researchers found that combining topical 5% minoxidil with intradermal triamcinolone microinjections significantly improved hair density in women with androgenetic alopecia compared to minoxidil alone. However, further research is necessary to confirm these findings in a larger population.
August 2025 in “Galen Medical Journal” In this study, among 2,000 patients with alopecia universalis, mesotherapy combined with systemic treatments like BMI, JAK inhibitors, and adalimumab showed the highest success in hair regrowth, particularly for children, with the combination therapy group achieving a 42% positive response rate.
July 2023 in “Biomolecules” This study established a novel in vivo "whisker follicle microinjection assay" using mouse whiskers to evaluate hair growth and pigmentation effects of various chemicals and proteins, identifying minoxidil, ruxolitinib, and RSPO1 as growth promoters, while deoxyarbutin inhibited pigmentation and Nbl1 emerged as a growth inhibitor.